SCHEMBL524200

SCHEMBL524200

CC(=O)N1CCCCC(O)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
EPHX2 P34913 2/20 0.42
EPHX1 P07099 1/20 0.42
HPGD P15428 1/20 0.39
DPP4 P27487 3/20 0.39
DPP7 Q9UHL4 1/20 0.39
GRM3 Q14832 1/20 0.38
HTT P42858 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
CHRNB3 Q05901 1/20 0.38
CHRNA6 Q15825 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21023431 1.00 CA12 (0.46) CA12CA1CA2CA9EPHX2
SCHEMBL3606966 0.94 CA12 (0.52) CA12CA1CA2CA9EPHX2
SCHEMBL20738739 0.94 CA12 (0.52) CA12CA1CA2CA9EPHX2
SCHEMBL4279033 0.94 CA12 (0.52) CA12CA1CA2CA9EPHX2
SCHEMBL50397 0.85
SCHEMBL524422 0.85
SCHEMBL4513056 0.85
SCHEMBL20973808 0.81 CA12 (0.47) CA12CA1CA2CA9HPGD
SCHEMBL22370881 0.81 CA12 (0.47) CA12CA1CA2CA9HPGD
SCHEMBL19582680 0.81 CA12 (0.47) CA12CA1CA2CA9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US claimed
EP-2222664-B1 CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2014-10-29 EP claimed
EP-2222664-A1 CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2010-09-01 EP claimed
WO-2009067401-A1 CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-28 WO claimed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US claimed
EP-3492451-B1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-11-03 EP disclosed
CN-105712977-B As histamine H3Cycloalkyloxypyridine compounds and heterocycloalkyloxy-pyridine compounds of receptor modulators 詹森药业有限公司 2021-06-29 CN disclosed
US-10323002-B2 Process for the preparation of histamine H3 receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2019-06-18 US disclosed
EP-3492451-A2 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-05 EP disclosed
EP-3216784-B1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-12-26 EP disclosed
US-20180022704-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-25 US disclosed
US-9809547-B2 Process for the preparation of histamine H3 receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2017-11-07 US disclosed
US-20140343279-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-11-20 US disclosed
US-8883776-B2 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2014-11-11 US disclosed
EP-2222664-B1 CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2014-10-29 EP disclosed
US-8748596-B2 Process for the preparation of histamine H3 receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-06-10 US disclosed
US-20120029189-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-02-02 US disclosed
EP-2222664-A1 CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2010-09-01 EP disclosed
WO-2009067401-A1 CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-28 WO disclosed
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131415-A1 CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH1 CA12 2482/4885CA1 2110/4885CA2 1833/4885
US-10323002-B2 Process for the preparation of histamine H3 receptor modulators HRH3, HRH4, HRH1 CA12 3896/4885CA1 1677/4885CA2 2711/4885
US-20180022704-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS HRH3, HRH4, HRH1 CA12 3896/4885CA1 1677/4885CA2 2711/4885
US-20140343279-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS HRH3, HRH4, HRH1 CA12 3896/4885CA1 1677/4885CA2 2711/4885
US-20120029189-A1 PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS HRH3, HRH4, HRH1 CA12 3896/4885CA1 1677/4885CA2 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.